Many breast cancers are characterised by amplification or overexpression of receptor tyrosine kinases such as ErbB2/human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor, insulin-like growth factor receptor and fibroblast growth factor receptor 1 that can drive tumour growth. Here, ERBB2 is linked to neoplasm.